SCIENTIFIC COMMITTEE ON CONSUMER SAFETY (SCCS)

Request for a scientific Opinion on children's exposure to Salicylic Acid (CAS No. 69-72-7, EC No. 200-712-3) from cosmetic products

Commission Department requesting the Opinion: Directorate-General for Internal Market, Industry, Entrepreneurship and SMEs

1. Background

The ingredient Salicylic Acid (CAS No. 69-72-7, EC No. 200-712-3) with the chemical name 'benzoic acid, 2-hydroxy' is used in cosmetic products with reported functions as a denaturant, hair and skin conditioning agent, exfoliant/keratolytic, anti-sebum agent, anti-dandruff/anti-seborrheic agent and a product preservative. Salicylic Acid is currently regulated under Annex III (entry 98) and Annex V (entry 3) with specific maximum concentrations and conditions of use.

Salicylic acid has been subject to safety evaluations by SCCNFP in 2002¹ in the context of the Cosmetic Directive 76/768/EEC for use other than preservative, while in 2018² it was assessed in view of its classification as a CMR cat.2 (Reprotoxic category 2) substance under Regulation (EC) No 1272/2008 (i.e., CLP Regulation). In particular, according to Article 15(1) of the Cosmetics Regulation 'the use in cosmetic products of substances classified as CMR substances, of category 2, under Part 3 of Annex VI to Regulation (EC) No 1272/2008 shall be prohibited. However, a substance classified in category 2 may be used in cosmetic products where the substance has been evaluated by the SCCS and found safe for use in cosmetic products'.

In 2022³, the SCCS re-assessed the safety of Salicylic Acid in view of its potential endocrine effects following a call for data where stakeholders submitted scientific evidence to demonstrate the safety of Salicylic Acid in cosmetic products. In the SCCS/1646/22 Opinion, the scientific committee confirmed the current allowed maximum concentration limits for Salicylic Acid for the relevant product types. However, the SCCS concluded that 'In the absence of exposure data of Salicylic Acid in cosmetic products for children, safety concerns have been noted for the younger age groups (between 3-10 years)'.

¹ https://ec.europa.eu/health/ph risk/committees/sccp/documents/out170 en.pdf

² https://ec.europa.eu/health/sites/default/files/scientific committees/consumer safety/docs/sccs o 223.pdf

³ https://health.ec.europa.eu/publications/salicylic-acid-cas-no-69-72-7-ec-no-200-712-3 en

In November 2023, the Commission received additional information from industry to defend the use of Salicylic Acid in cosmetic products used in children of 3-10 years of age. Cosmetic products intended for children between 3-10 years cover (i) *leave-on* products such as face cream, hand cream, body lotion, (ii) *rinse-off* products such as hand soap, shower gel, shampoo and hair conditioner, and (iii) *oral care* products such as toothpaste and mouthwash with the latter allowed only for children above 6 years. The Commission, therefore, requests the SCCS to carry out a safety assessment on Salicylic Acid in view of the new information provided.

2. Terms of reference

- (1) In light of the data provided and taking under consideration the conclusions of the SCCS/1646/22 Opinion on children exposure, does the SCCS consider Salicylic Acid safe for children between 3-10 years of age:
 - (a) when used as a preservative in cosmetic products up to a maximum concentration of 0.5%?
 - (b) when used for purposes other than inhibiting the development of microorganisms at a concentration up to:
 - i. 3.0 % for cosmetic rinse-off products
 - ii. 2.0 % for cosmetic leave-on products except body lotion and oral products, and
 - iii. 0.5 % for body lotion and oral products
- (2) Alternatively, what is according to the SCCS the maximum concentration of Salicylic Acid that is considered safe for children 3-10 years of age?
- (3) Does the SCCS have any further scientific concerns with regard to the use of Salicylic Acid in cosmetic products and children's exposure?

3. Deadline

8 months.

4. Supporting documents

Salicylic Acid and children exposure dossier

→ The SCCS approved this mandate during plenary meeting on 27 March 2024.